Various health and research agencies in the United States have begun work to create and develop a safe vaccine to combat COVID-19. Since the beginning of this year there has been a growing number of clinical trials for COVID-19 because of its increase incidence rate and mortality.
The first-in-human vaccine trial was administered in early March by the National Institute of Allergy and Infectious Diseases (NIAID) in Seattle, Washington. This vaccine trial is being conducted with 45 healthy males and non-pregnant women, ages 18-55 over approximately six weeks. The vaccine trial is expected to end in June 2021.
Additionally, the U.S. Department of Human and Health Services is working with New Jersey-based Janssen Research and Development, part of Johnson & Johnson, and Moderna of Cambridge, MA. The Biomedical Advanced Research and Development Authority, part of the HHS Office of the Assistant Secretary for Preparedness and Response, will support Phase 1 clinical trial of Janssen’s COVID-19 investigational vaccine.
This clinical trial will evaluate the vaccine’s safety in healthy adult volunteers and its ability to induce an immune response. This trial is expected to begin in Fall 2020, with the goal of making COVID-19 vaccinations available for emergency use in the U.S. in early 2021.
For more information about the COVID-19 vaccine clinical trials visit this site.